Clinical Policy: Infusion Therapy Site of Care Optimization
Customize your policy alerts
Sign up for Arizona Complete Health Policy AZ. CP.PHAR.493 alerts
Get alerted when Policy AZ. CP.PHAR.493 changes without checking for updates manually.
Monitor payer policy activity
Defines medical necessity criteria and site-of-care authorization rules for outpatient intravenous or injectable specialty infusion therapies for Arizona Complete Health (Arizona Medicaid). Applies to providers requesting coverage for infusion administration location and related specialty drugs.
Updated description to include Place of Service Codes for OP billing include home, office, pharmacy, and hospital for medical billing.
In Section I.A.1 updated OR to AND to clarify that both 1 and a or b or c or d or e when reviewing.
Added Continued approval portion that was not previously provided.
Coverage Criteria
Initial Approval Criteria
Patient IV or injectable therapy is medically necessary when ALL of the following are met:
See subnodes for permitted justifications.
Justifications for higher-intensity outpatient site
- a: Request is for administration of the initial dose of the treatment or restart of treatment after a >=6-month disruption for a short duration (e.g., 4 weeks).restart >=6 months
Provider must submit request for initial visit with plan for continued administration at home infusion or ambulatory infusion suite.
- b: Documentation that the FDA‑approved indication requires outpatient hospital administration.
- c: Submitted documentation that home‑based therapy or ambulatory infusion center is a health risk for the member due to physical or behavioral impairment.
Examples include severe venous access issues (vein finder not available), lack of caregiver access, cardiopulmonary disorder, inability to tolerate IV fluid loads, cognitive concerns impacting patient safety; not an exhaustive list.
- d: Submitted medical or infusion records documenting severe or life‑threatening adverse events that were non‑responsive to pre‑medications, analgesics, steroids, antihistamines, fluids or infusion rate reductions.
Examples include seizures, anaphylaxis with no other therapy options, myocardial infarction, renal failure. Non‑qualifying examples: trypanophobia, pediatrics, preference/convenience, frequent laboratory monitoring, continuation of services from previous plan.
Continuation Criteria
For continuation of services at the requested location:
Approval duration: Up to one year or length of approval for the drug.
Initial Therapy
Initial approval requires ALL of the following (updated rules):
Section I.A.1 revised to require both FDA site‑of‑care approval and drug availability; see Initial Approval Criteria subnodes for acceptable justifications and examples.
Continuation Therapy
Continued approval (updated):
See full policy for specific continued‑therapy documentation requirements.
AZ Medicaid Reinsurance drugs identified in Appendix B are excluded from the medical benefit (buy/bill) and must be billed through the pharmacy benefit. Providers requesting administration of a drug listed as AZ Medicaid Reinsurance should route drug acquisition and billing via the pharmacy benefit rather than medical buy/bill. Prior authorization for site of care remains required when the drug is eligible for alternative sites of care; documentation must demonstrate that a lower-intensity site (home infusion or ambulatory infusion center) is unavailable or that specialty pharmacy cannot provide the drug before approval of a higher-intensity outpatient site is considered.
The policy clarifies examples of non-qualifying reasons for approval of a higher-intensity outpatient hospital or non-hospital outpatient office/facility. Specifically, routine situations such as member preference or convenience, continuation of services from a previous plan, or other administrative reasons do not meet medical necessity for escalation of site of care. These items are explicitly listed as non-qualifying examples and should not be used in lieu of the required clinical justifications for a higher-intensity site.
The policy notes that certain clinical or patient-specific situations may justify a higher-intensity site when documented: for example, trypanophobia (fear of needles) is explicitly listed as a non-qualifying example and therefore does not by itself justify site escalation, whereas pediatrics are also listed among non-qualifying examples unless other medical criteria are met. When clinical evidence demonstrates that home or ambulatory infusion is a health risk (e.g., severe venous access issues, lack of caregiver, cardiopulmonary disorder, inability to tolerate IV fluids, cognitive concerns) or when initial dose/restart after a ≥6‑month disruption is required, higher-intensity administration may be approved with supporting documentation.
Requests that do not meet any of the stated medical necessity reasons for a higher-intensity outpatient site are considered not medically necessary. The policy directs that such requests should be provided in an alternate, less intensive site of care. Examples of non-medical-necessity reasons include trypanophobia, pediatrics (absent other qualifying clinical criteria), patient preference/convenience, frequent laboratory monitoring, and continuation of services from a previous plan; these alone do not meet criteria for inpatient or outpatient hospital administration.
Initial Therapy Criteria
Initial Therapy
Initial administration at a higher‑intensity outpatient site may be approved when ALL general requirements are met and ONE of the following specific conditions is documented:
Initial higher-site justifications
- a: Initial dose administration or restart after a >=6‑month disruption for a short duration (e.g., 4 weeks).restart >=6 months
Provider must request initial visit with plan for continued administration at home infusion or ambulatory infusion suite.
- b: The FDA‑approved indication requires outpatient hospital administration.
- c: Home‑based therapy or ambulatory infusion center poses a health risk due to physical or behavioral impairment.
Examples: severe venous access issues (vein finder unavailable), lack of caregiver, cardiopulmonary disorder, inability to tolerate IV fluids, cognitive concerns affecting safety; list not exhaustive.
- d: Severe or life‑threatening adverse events documented that were non‑responsive to pre‑medications, analgesics, steroids, antihistamines, fluids or infusion‑rate reductions.
Examples: seizures, anaphylaxis without other options, myocardial infarction, renal failure. Non‑qualifying reasons: trypanophobia, pediatrics, convenience, frequent lab monitoring, continuation from previous plan.
Initial therapy
Initial authorization rules (updated):
Specialty pharmacy may be used as a drug source per updates; See Appendix B for drugs subject to these rules.
Continuation Therapy Criteria
Continuation Therapy
Continuation of therapy at the requested site requires documentation:
Approval duration: Up to one year or length of approval for the drug.
Coding and Drug Appendix
| J0129 | Abatacept (Orencia) |
| J0172 | Aducanumab-Avwa (Aduhelm) |
| J0180 | agalsidase beta (Fabrazyme) |
| J0202 | alemtuzumab (Lemtrada) |
| J0218 | Olipudase Alfa (Xenopozyme) |
| J0219 | Avalglucosidase alfa-ngpt (Nexviazyme) |
| J0221 | algucosidase alfa (Lumizyme) |
| J0222 | patisiran (Onpattro) |
| J0223 | givosiran (Givlaari) |
| J0224 | lumasiran (Oxlumo) |
| J2327 | risankizumab-rzaa (Skyrizi) |
| J2329 | ublituximab-xiiy (Briumvi) |
| J2350 | ocrelizumab (Ocrevus) |
| J2356 | tezepelumab-ekko (Tezspire) |
| J2357 | omalizumab (Xolair) |
| J2406 | oritavancin (Kimyrsa) |
| J2407 | oritavancin (Orbactiv) |
| J2426 | paliperidone injection (Invega Sustenna) |
| J2469 | palonosetron (Aloxi) |
| J2501 | paricalcitol (Zemplar) |
Provider Actions and Requirements
Prior Authorization Required
Prior Authorization Required — Prior authorization is required to request an inpatient/outpatient hospital or non-hospital outpatient site for IV/injectable therapy. Requests for specialty infusion therapies listed in Appendix B require prior authorization; initial approvals require FDA approval for the requested site of care when applicable.
- Prior authorization required for drugs listed in Appendix B
- Initial approval requires FDA approval for site of care when applicable
- Specialty pharmacy availability and member safety at the proposed site are considered
Prior Authorization for Appendix B Drugs
Prior authorization required for specialty infusion therapies listed in Appendix B. For new start requests, provider must submit request for the initial visit with documentation that continued administration will occur at home infusion or an ambulatory infusion center when appropriate.
- Appendix B lists specialty infusion drugs requiring prior authorization
- Provider must request initial visit and indicate plan for continued home or ambulatory administration when applicable
Site Escalation Logic
Site-of-care escalation logic: If a lower-intensity site (home infusion or an ambulatory infusion center) is available and a specialty pharmacy can supply the drug, those less intensive sites are preferred over outpatient hospital settings. If no lower-cost site or specialty pharmacy availability exists, a higher-intensity site may be authorized when criteria are met.
- Home infusion and ambulatory infusion centers are preferred when clinically appropriate and available
- Specialty pharmacy must be able to provide the drug for lower-intensity site to be preferred
Step Therapy and Sourcing
Step therapy / sourcing: Step therapy and site-of-care considerations include specialty pharmacy as a source if the provider requires outpatient hospital or higher-intensity site and specialty pharmacy cannot provide the drug or member setting is unsafe.
- Specialty pharmacy inclusion in sourcing decisions
- If specialty pharmacy can supply drug and member setting is safe, lower-intensity site should be used
Required Documentation
Required Documentation — Provider must submit documentation (office chart notes, lab results, infusion records, or other clinical information) supporting that the member meets all applicable approval criteria, including evidence that lower-intensity sites were considered or are unsuitable and any FDA approvals required for site of care.
- Office chart notes, lab results, infusion records or other clinical information
- Documentation that home or ambulatory infusion is unsafe or unavailable when requesting higher-intensity site
- For adverse events: records documenting severity and response to pre-medications or interventions
Required Submission for New Starts
Required submission for new starts — For initial administration or restart after a ≥6-month disruption, the provider must submit the request indicating the initial visit and plan for continued administration at home infusion or ambulatory infusion center when clinically appropriate.
- Initial dose or restart after ≥6 months requires documentation and plan for continued site of care
- Provider must indicate if FDA indication requires outpatient hospital for administration
Denial Triggers
Denial Triggers and Denial Guidance — Requests that do not meet the initial approval criteria should be provided in an alternate, less intensive site of care and may be denied. Requests may be denied if: initial criteria are not met, the drug is not available from a specialty pharmacy when required, FDA approval for the site of care (when applicable) is lacking, or member factors (safety at proposed site) are not supported by documentation.
- Denial if initial approval criteria not met; alternate less intensive site should be used
- Denial if FDA-required site authorization is absent when applicable
- Denial if specialty pharmacy cannot supply drug and lower-intensity site was not considered or is available
Site of Care and Place of Service
Render services in the least intensive appropriate setting
Services should be rendered in the least intensive appropriate setting; alternative less intensive sites explicitly include home infusion, physician office, and ambulatory infusion centers, with hospital outpatient reserved only when justified.
- Least intensive sites: home infusion, ambulatory infusion center, physician office
- Higher-intensity outpatient hospital/office only with documented justification per policy
Place of Service codes and specialty pharmacy as drug source
Place of Service codes for outpatient billing include Pharmacy (01), Office (11), Home (12), Off-campus Outpatient Hospital (19), On-campus Outpatient Hospital (22), and ESRD Facility (65). The policy allows specialty pharmacy to be used as the drug source when appropriate.
- POS codes listed: Pharmacy (01), Office (11), Home (12), Off‑campus OP hospital (19), On‑campus OP hospital (22), ESRD facility (65)
- Specialty pharmacy may serve as the drug source for outpatient administration per updated sourcing rules
Step Therapy and Justifications
| Justification for higher-intensity outpatient site | Notes / examples | Coverage status |
|---|---|---|
| Initial dose administration or restart after >=6-month disruption for short duration (e.g., 4 weeks) | ||
| Provider must request initial visit with plan for continued administration at home infusion or ambulatory infusion suite; restart threshold = 6 months | ||
| Authorized when documented | ||
| FDA‑approved indication requires outpatient hospital administration | ||
| Must document that the FDA‑approved indication requires administration in an outpatient hospital setting | ||
| Authorized when documented | ||
| Home‑based therapy or ambulatory infusion center poses a health risk due to physical or behavioral impairment | ||
| Examples: severe venous access issues (no vein finder), lack of caregiver, cardiopulmonary disorder, inability to tolerate IV fluids, cognitive concerns impacting safety | ||
| Authorized when documented | ||
| Severe or life‑threatening adverse events not responsive to pre‑medications or supportive measures | ||
| Examples: seizures, anaphylaxis with no other options, myocardial infarction, renal failure; document failure of pre‑meds/analgesics/steroids/antihistamines/fluids/infusion rate reductions | ||
| Authorized when documented |
| Step / sourcing consideration | Updated guidance | Coverage status |
|---|---|---|
| Use least intensive appropriate setting first (home infusion or ambulatory infusion center) if available and specialty pharmacy can supply the drug | ||
| If home infusion or ambulatory center is available and specialty pharmacy can provide the drug, those lower‑intensity sites should be used; higher‑intensity site requires documented justification per listed criteria | ||
| Neutral (requires criteria) | ||
| Include specialty pharmacy as an acceptable drug source for outpatient hospital or office administration requests | ||
| Policy updated to explicitly allow specialty pharmacy as a source when provider requires outpatient hospital or office administration; see main criteria for required documentation | ||
| Neutral (requires criteria) |
Biosimilar Notes
Rituximab first visit in AIS (includes biosimilars)
Rituximab (Rituxan) requires the first visit in an ambulatory infusion suite (AIS); this applies to rituximab and its biosimilars.
- J9312 (rituximab) noted as first visit in AIS; biosimilars included
Definitions
Background
Specialty infusion therapy refers to intravenous or injectable medications used to manage complex or chronic conditions. This policy promotes delivering care in the least intensive appropriate setting and requires prior authorization when escalation to an in-network outpatient hospital or non-hospital outpatient office/facility is requested. Initial administration at a higher-intensity site may be authorized only when documented justifications are met (for example, initial dose or restart after a ≥6‑month disruption, FDA indication requiring hospital administration, documented health risk for home therapy, or severe/life‑threatening adverse events not responsive to standard mitigations). Providers must submit clinical documentation to support site-of-care requests and consider specialty pharmacy availability and Place of Service billing guidance when arranging administration.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.